Microstructure Imaging, INC

Microstructure Imaging, Inc. (MICSI) develops FDA 510(k)-cleared software solutions that enhance MRI image quality through advanced denoising algorithms. The company's primary product, MICSI-RMT (K241121), is a clinical-grade software suite designed to improve diffusion-weighted and functional MRI imaging across neuroimaging and prostate applications. The platform leverages a patented MP-PCA (Marchenko-Pastur Principal Component Analysis) algorithm that reduces noise by approximately 4-fold while preserving anatomical integrity and diagnostic signal fidelity. MICSI-RMT integrates quantitative analysis modules supporting weighted linear least squares and Bayesian fitting techniques for diffusion-weighted imaging, alongside secure DICOM data routing for seamless workflow integration. Key clinical benefits include enhanced image resolution without hardware upgrades, reduced image acquisition requirements (enabling shorter scan times and improved patient comfort), extended operational lifespan of 1.5T and 3.0T MRI systems, and improved diagnostic sensitivity. The software is compatible with standard MRI protocols on GE and other major platforms. Clinical validation is supported by peer-reviewed publications in high-impact journals (Neuroimage, Radiology, Investigative Radiology) and multiple regulatory citations. MICSI targets hospital imaging departments, diagnostic centers, and research institutions seeking cost-effective image quality improvements and operational efficiency gains without capital equipment replacement.